🔗 Share this article

The recently developed medications for gonorrhoea in many years are being hailed as a "huge turning point" in the battle against superbug strains of the bacteria, according to researchers.

A Global Challenge

The sexually transmitted infection are on the rise globally, with data suggesting over 82 million new cases annually. Notably increased rates are seen in the African continent and nations within the World Health Organization's designated area, which includes China and Mongolia to New Zealand. Across England, cases have reached a historical peak, while infection numbers across Europe in 2023 were significantly elevated compared to figures for 2014.

“The clearance of new treatments for gonorrhoea is an critical and opportune step in the context of growing infection rates, the spread of superbugs and the highly restricted therapeutic options currently available.”

Medical experts are particularly alarmed about the rise in antibiotic-resistant strains. The WHO has designated it as a "priority pathogen". Ongoing monitoring showed that the effectiveness of key first-line drugs like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Recent Therapies Secure Approval

Zoliflodacin, alternatively called a brand name, was approved by the US FDA in mid-December for use against gonorrhoea. This STI can lead to significant complications, including the inability to conceive. Experts believe that focused deployment of this new drug will help slow the development of resistance.

Another new antibiotic, originating from the pharmaceutical company GSK, also received approval in the same week. This treatment, which is employed against urinary tract infections, was proven in research to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Development Model

This new treatment stemmed from a new, not-for-profit approach for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the drug firm Innoviva to see it through.

“This milestone represents a major breakthrough in the management of highly resistant gonorrhoea, which previously has been outpacing medical innovation.”

Research Study Data and Worldwide Availability

As per results published in a prominent scientific publication, the new drug eradicated the vast majority of genital gonorrhoea infections. This places it at an equal footing with the typical regimen, which uses an injection and a pill. The research enrolled nearly 1,000 patients from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its collaboration, the non-profit has the ability to license and sell the drug in a wide range of low-income and middle-income countries.

Medical professionals directly involved have shared hope. Access to a easy-to-administer therapy of this kind is hailed as a "revolutionary step" for managing the epidemic. This is viewed as essential to lessen the impact of the infection for people and to prevent the spread of highly drug-resistant gonorrhoea around the world.